Dosimetric comparison of different radionuclides used in metastatic bone disease treatment
Citation
Kökkülünk, H. T. (2022). Dosimetric comparison of different radionuclides used in metastatic bone disease treatment. Current Radiopharmaceuticals.Abstract
Introduction: In this study, it is aimed to determine the critical organ doses in 223Ra, 89Sr, 153Sm and 32P treatments via dosimetry using the phantoms Material and methods: The OpenDose is used to calculate S values (mGy MBq-1s-1) for bone surface, red bone marrow, urinary bladder wall, testes, ovaries, uterus and kidneys using male (ICRP110AM) and female (ICRP110AF) phantoms. The cortical thoracic spine is modeled as metastasis. Moreover, the absorbed doses are computed via MIRD formalism according to the activities of 3.3, 148, 2220 and 370 MBq for ICRP110AM and 4.015, 148, 2701 and 370 MBq for ICRP110AF in 223Ra, 89Sr, 153Sm and 32P treatments, respectively.
Results: Whilst the maximum bone surface doses are found as 1.22E+02 and 8.51E+01 mGy at 32P treatment, the minimum bone surface doses are calculated as 8.42E-02 and 8.26E-02 mGy at 223Ra. In terms of the comparison of red bone marrow, urinary bladder wall and kidney doses, 153Sm and 89Sr treatments are shown the maximum doses with 2.45E-03, 1.50E-03, 3.23E-07, 5.45E-06, 1.20E-01, 1.49E-01 mGy and the minimums with 3.46E-05, 1.99E-05, 6.33E-09, 8.77E-09, 1.19E-04, 1.15E-04 mGy, respectively. The maximum testes and ovaries-uterus doses are found as 6.17E-08, 7.40E-06, 3.46E-07 mGy in 153Sm treatment, and minimum testes and ovaries doses as 1.70E-09, 1.34E-07 mGy in 223Ra. The minimum uterus dose with 7.03E-09 mGy is determined in 89Sr treatment.
Conclusion: It is observed that 223Ra produces low critical organ doses in the treatment of painful bone metastasis. Among the beta-emitting radionuclides, 89Sr stands out by showing optimal dosimetric results.